T1	Participants 13 29	multiple myeloma
T2	Participants 475 927	Patients with untreated stage I MM (defined according to Durie and Salmon) were randomised between being followed without cytostatics until the disease progressed and receiving six courses of melphalan and prednisone (MP-P) just after diagnosis; stage II patients were uniformly treated with MPH-P and stage III patients were randomised between MPH-P and four courses of combination chemotherapy with Peptichemio, vincristine and prednisone (PTC-VCR-P)
T3	Participants 948 967	responsive patients
T4	Participants 1196 1248	patients originally treated with MPH-P for induction
T5	Participants 1335 1475	43.8% (42.2% in 206 stage I, II and III patients treated with MPH-P and 48.0% in 75 stage III patients treated with combination chemotherapy
T6	Participants 1747 1851	stage I patients who were initially left untreated and in t hose who received MPH-P just after diagnosis
T7	Participants 1902 1977	stage III patients receiving MPH-P and in those on combination chemotherapy
T8	Participants 2240 2247	stage I
T9	Participants 2268 2276	stage II
T10	Participants 2300 2318	stage III patients
